The Role of Ubiquitin and Ubiquitin-Like Modification Systems in Papillomavirus Biology by Wilson, Van G.
Viruses 2014, 6, 3584-3611; doi:10.3390/v6093584 
 
viruses 
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
The Role of Ubiquitin and Ubiquitin-Like Modification Systems 
in Papillomavirus Biology 
Van G. Wilson 
Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health 
Science Center, 8447 HWY 47, Bryan, TX 77807, USA; E-Mail: wilson@medicine.tamhsc.edu;  
Tel.: +1-979-436-0310; Fax: +1-979-436-0086 
Received: 22 August 2014; in revised form: 17 September 2014 / Accepted: 18 September 2014 / 
Published: 24 September 2014 
 
Abstract: Human papillomaviruses (HPVs) are small DNA viruses that are important 
etiological agents of a spectrum of human skin lesions from benign to malignant. Because 
of their limited genome coding capacity they express only a small number of proteins, only 
one of which has enzymatic activity. Additionally, the HPV productive life cycle is 
intimately tied to the epithelial differentiation program and they must replicate in what are 
normally non-replicative cells, thus, these viruses must reprogram the cellular environment 
to achieve viral reproduction. Because of these limitations and needs, the viral proteins have 
evolved to co-opt cellular processes primarily through protein-protein interactions with 
critical host proteins. The ubiquitin post-translational modification system and the related 
ubiquitin-like modifiers constitute a widespread cellular regulatory network that controls the 
levels and functions of thousands of proteins, making these systems an attractive target for 
viral manipulation. This review describes the interactions between HPVs and the ubiquitin 
family of modifiers, both to regulate the viral proteins themselves and to remodel the host 
cell to facilitate viral survival and reproduction. 
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1. Introduction –— Human Papillomaviruses 
The human papillomaviruses (HPVs) are important pathogens with clinical manifestations ranging 
from benign to malignant lesions [1,2]. Over 170 different types have been sequenced with many more 
isolates identified but not yet classified [3]. The existing HPVs are classified into five genera, 
Alphapapillomaviruses, Betapapillomaviruses, Gammapapillomaviruses, Mupapillomaviruses, and 
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Nupapillomaviruses, with the majority falling into genus alpha and genus beta. Most of the alpha group 
viruses infect mucosal epithelium while the beta types exhibit tropism primarily for cutaneous 
epithelium. Among the mucosal types a functional distinction exists between types that are highly 
associated with the development of cervical cancer, the so-called high-risk types, and the remaining 
nononcogenic, low-risk types. Because of their contribution to the development of cervical cancer, 
research has often focused heavily on the high risk types, particularly the most prevalent types, 16 and 
18. More recently, a growing body of evidence linking cutaneous beta type HPVs to skin cancers [4] has 
led to increased examination of the biology and molecular biology of the beta HPVs. What has arisen 
from studies across multiple HPV types is that there are both common and type-specific features 
reflecting the great diversity of types and their biological niches [5–7]. 
A common feature of all papillomaviruses is a small, double-stranded, circular genome of about 8000 
base pairs containing a single origin of replication [8]. These small genomes encode a limited number 
of proteins that are classified as either early or late depending on their time of expression. The early 
region of the genome contains open reading frames (ORFs) E1, E2, E4, E5, E6, and E7, and the early 
protein functions include viral genome replication, transcriptional regulation, and modulation of the host 
cell environment to favor viral replication and/or persistence (Figure 1). E6 and E7 gene products are 
particularly important for reprogramming the host cell, and for the high risk HPVs their E6 and E7 
products constitute the predominant oncoproteins. There are only two late proteins, L1 and L2, and these 
are the viral capsid structural proteins [9,10]. Given the very limited repertoire of viral proteins, the 
HPVs have evolved to be highly dependent upon the host cells to supply needed functions and enzymatic 
activities. Much more detailed information about HPV proteins and their functions can be found in 
several recent reviews [11–16]. 
 
 
Figure 1. HPV genome organization and function. Shown is a linearized HPV genome with 
the relative genomic locations of the early (E) and late (L) ORFs indicated. The NCR is the 
noncoding region that contains the viral replication origin and transcriptional regulatory 
elements. Functions associated with the various ORFs are listed in the box below 
the genome. 
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HPVs have a complex lifecycle that is intimately connected to the differentiation program of 
skin [17]. Establishment of infection requires viral entry into the replicative basal cells where the viral 
genome can persist episomally in the host cell nucleus [18]. Subsequent stages of the productive lifecycle 
occur in the subrabasal layers as differentiation progresses. Normally, these differentiating cells are 
nondividing and would not provide the replicative machinery and S phase environment required by the 
HPVs for their DNA replication, thus, a requirement of these viruses is to push the cells back into a 
proliferative state [19]. Additionally, HPVs must ensure appropriate expression of the viral proteins at 
different differentiation stages, effective assembly of new virions, and avoidance of host defense 
mechanisms [20]. Surprisingly, these viruses have only one enzymatically active protein, E1, which has 
helicase activity for viral genome replication [21–23]. Consequently, the actions of the other viral 
proteins are mediated entirely through protein-protein interaction, and this review will focus on how the 
HPV proteins interact with the ubiquitin and related ubiquitin-like modification systems. 
2. Overview of the Ubiquitin Superfamily 
All viruses have common missions that they must accomplish in order to successfully reproduce, 
including optimizing viral gene expression, promoting viral genome replication, and avoiding or 
abrogating host defense systems. At each of these steps viruses typically have evolved numerous 
complementary and/or redundant mechanisms to co-opt cellular proteins and machinery to support the 
viral lifecycle. Because of this dependence on host cells, viruses often target cellular systems with broad 
and important regulatory functions such as the ubiquitin super family [24]. This superfamily is 
characterized by small protein modifiers that are covalently attached to proteins substrates through a 
series of biochemically similar steps (Figure 2). These modifiers include ubiquitin and a series of 
ubiquitin-like proteins (Ubls), such as SUMOs [25], ISG15 [26], NEDD8 [27], FAT10 [28], and others 
[29]. The first step in the conjugation process is activation of the modifier through an ATP-dependent 
reaction that forms a thioester linkage between the modifier and the activation enzyme (E1) [30]. 
Subsequently the modifier is transferred to the conjugation enzyme (E2), again through a thioester 
linkage [31]. Finally, the modifier is transferred to the substrate using an E3 ligase that provides substrate 
specificity [32]. This final conjugation of the modifier to the substrate occurs through an isopeptide bond 
linking the C-terminus of the modifier with the epsilon amino group of a lysine residue in the target 
protein. Depending on the substrate, more than one lysine may be modified and more than one type of 
modifier may be utilized; in some cases the different modifications occur on separate lysine residues 
while in other cases different modifiers compete for the same lysine, often with opposing functional 
effects [33,34]. Additionally, depending on the modifier used both mono- and poly-chains of the 
modifier can be formed resulting in different outcomes for the substrate [35,36].  
The prototype of this superfamily is ubiquitin, a 76 amino acids protein. Polyubiquitination targets 
proteins for proteosomal degradation and is a key cellular mechanism for removing damaged proteins 
and for regulating protein activity [37]. Ubiquitin chains can be removed by deubiquitinating enzymes 
(DUBs), thus, the balance between the modification and demodification reactions can be important for 
controlling substrate levels, including viral proteins [24,38]. In addition to ubiquitin, the SUMOs [39,40] 
and ISG15 [41] are the other two Ubls that have been implicated as modifiers involved in HPV viral 
processes. There are four human SUMO genes encoding SUMOs 1-4 [42], though SUMO 4 appears to 
have limited tissue expression [43] and has been much less studied than the other three. The processed 
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forms of SUMOs 2 and 3 are 97% identical, while both are approximately 50% identical to SUMO1. 
While highly similar and often treated interchangeably in many studies, functional and biological 
differences have emerged for the three predominant SUMO types [44–47]. Consequently, the possibility 
of type-specific effects on substrates should be kept in mind when interpreting sumoylation studies. Like 
ubiquitin, SUMO moieties can be removed from substrates by a set of desumoylating enzymes known 
as SENPs (sentrin proteases) [48]. Lastly, mature ISG15 is a 157 amino acid ubiquitin-like modifier 
whose expression is highly stimulated by type I interferon [26]. While ISG15 modification is now known 
to impact a variety of cellular processes, its original discovery as an interferon-stimulated gene has 
focused a great deal of work in this field towards its role in viral infections where it has an antiviral 
effect [41]. 
 
 
Figure 2. Schematic of the general cascade for modification by ubiquitin and ubiquitin-like 
(Ubl) modifiers. E1, E2, and E3 are the activating enzyme, conjugating enzyme, and ligase, 
respectively for the various Ubl pathways; the number of distinct enzymes at each step 
various for the particular modifier system. M represents ubiquitin or any other Ubl. S is the 
substrate and D is the demodifying enzyme that removes the modifier and returns the 
substrate to the unmodified form. See the text for more details about each step in the 
modification/demodification process. 
3. Modification of HPV Viral Proteins by Ubiquitin and Ubiquitin-Like Modifiers (Ubls) 
As for cellular gene products, the expression levels of viral proteins need to be highly regulated to 
coordinate their individual protein activities with the functional stages of the viral life cycle. This 
regulation typically occurs at both transcriptional and post-transcriptional levels. For HPVs, the viral 
early proteins tend to be expressed at relatively low levels and have short half-lives (Sections 3.1.–3.6.), 
while the L1 [49] and L2 [50] late proteins are much more stable (Section 3.7.). Proteasome inhibitor 
studies showed that the instability of these viral early proteins is proteasome dependent, and studies on 
individual HPV early proteins have shown that ubiquitination is a key element in targeting these proteins 
to the proteasome [51–54]. In combination, these results indicate that the ubiquitin-proteasome system is a 
key mechanism used by HPVs to regulate the intracellular levels of the viral gene products at the  
post-translational level. In addition to modification by ubiquitination, several HPV proteins are modified 
by sumoylation [39]. Sumoylation does not directly lead to degradation of the viral substrates, but does 
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modulate biological functions. Both the ubiquitin and SUMO systems are utilized by the host cell to 
regulate aspects of cell cycle [55–57] and differentiation [57,58], and HPVs presumably take advantage 
of these systems to coordinate the levels of viral proteins with critical aspects of host cell cycle and 
epithelial cell differentiation. Alternatively, in some cases, these Ubl modifications may be antiviral in 
nature as the host cell attempts to reduce the level or activities of viral proteins as a protective measure. 
More specific details concerning the modification of the individual early proteins by ubiquitin and 
SUMO are presented below. 
3.1. The E1 Proteins 
E1 proteins are replication helicases that nucleate the formation of viral genome replication 
complexes and are essential for papillomavirus replication [13]. An early study revealed that the bovine 
papillomavirus (BPV) E1 protein was an unstable protein that was ubiquitinated and degraded via 
proteasomes [51]. In these studies, E1 was stabilized by association with the cyclin E/Cdk2 complex, 
apparently simply through complex formation, as Cdk2 kinase activity and E1 phosphorylation were not 
required for the protection from degradation. Under conditions which supported BPV origin-dependent 
DNA replication, E1 again became rapidly degraded, possibly as a consequence of dissociation from the 
cyclin E/Cdk2 complex. The elongation phase of DNA synthesis was required for E1 degradation, 
suggesting that E1 may dissociate from the cyclin E/Cdk2 complex at the completion of each round of 
genome replication. Subsequently, the anaphase-promoting complex (APC) was shown to be a primary 
E3 ligase for E1, specifically the APCCdh1 complex [59]. E1 interaction with, and degradation mediated 
by, the APC complex was dependent upon a KEN box and a D box within E1. As these motifs are highly 
conserved among HPV E1 proteins this suggests that the APC complex may be a universal regulator of 
E1 stability. However, comparable studies have not been directly done for HPV E1 proteins, thus, 
virtually nothing is known about the specific components of the ubiquitin-proteasome system that promote 
degradation of the human papillomavirus types. 
In addition to modification by ubiquitin, E1 proteins are also substrates for SUMO, first shown for 
BPV E1 [60] and then for HPV 11 [61]. E1 sumoylation requires direct interaction with the SUMO 
conjugase, Ubc9 [60], and the interaction appears to be enhanced by E1 oligomerization [62]. 
Sumoylation of E1 is also stimulated by three SUMO ligases of the PIAS (protein inhibitor of activated 
STAT) family, suggesting that some or all of the members of this family may be the authentic in vivo 
ligases for E1 proteins [61]. While the available evidence strongly supports that E1 proteins can be 
sumoylated as a consequence of their interaction with Ubc9, the extent of E1 sumoylation is limited and 
the functional consequences of this modification are unclear. Sumoylation was originally reported to be 
required for nuclear localization of E1 [63], however, subsequent studies did not confirm this phenotype 
[62,64]. Intriguingly, all E1 mutants defective for Ubc9 binding are also impaired for DNA replication 
[62]. This could indicate that E1 sumoylation is required for some step in viral genome replication, but 
could also reflect requisite sumoylation of some other replication factor, such as PCNA (proliferating 
cell nuclear antigen) [65]. In this latter case E1 could be recruiting Ubc9 to the replication complex to 
redirect its activity to a host substrate critical for the viral replication process. 
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3.2. The E2 Proteins 
E2 is a central regulatory factor for papillomaviruses and its expression is tightly regulated at  
multiple levels, including protein turn over. Ubiquitination and proteosomal degradation leading to a 
short half-life was first demonstrated for bovine papillomavirus E2 [66]. Similar ubiquitination and 
proteosomal degradation leading to short half-lives has been shown for E2 proteins from both high risk 
(types 16, 18, and 31) and low risk (types 6 and 11) HPVs, and their rapid degradation is dependent upon 
sequences within the amino terminal transactivation domain [52,67,68]. Importantly, E2 protein levels 
are cell cycle regulated with degradation occurring specifically at the end of G1 phase, and this 
degradation is mediated at least in part via interaction with the SCFSkp2 ubiquitin ligase [69]. High risk 
E2 proteins also associate with the Mdm2 ligase [70] and the APC/C ubiquitin ligase [71], though E2 
does not appear to be a direct substrate for either ligase. For APC/C, E2 interacts with the activators, 
Cdc209 and Cdh1, and inhibits APC/C activity leading to the stabilization of several substrates involved 
in cell cycle control and chromosomal instability, including Skp2 [71]. This suggests a possible feedback 
mechanism to control E2 levels in cycling basal keratinocytes whereby E2 acts on APC/C to increase 
Skp2 which subsequently leads to E2 degradation via the SCFSkp2 ligase [69]. In contrast, in 
differentiated keratinocytes where Skp2 is not expressed this feedback would absent thus contributing 
to the observed increase in E2 levels in the upper layers of the epithelium [72]. 
While HPV 18E2 was shown to interact with the SCFSkp2 ubiquitin ligase that contains cullin1, HPV 
16E2 associated with cullin3 but only weakly if at all with cullin1 [73]. Inhibition of cullin3-based E3 
ligases with a dominant-negative CUL3 led to reduced ubiquitination and a significantly increased half-
life for 16E2, suggesting that 16E2 degradation is mediated via a cullin-3 containing ubiquitin ligase. 
Whether or not 18E2 and 16E2 are actually ubiquitinated via different E3 ligases, or if there is 
redundancy in which ligases can target E2 proteins, remains to be determined. Interestingly, Brd4, an 
activator of E2 transcriptional activity, blocks the interaction between E2 and cullin-3 resulting in 
increased stability of E2, presumably through reduced ubiquitination [73]. Similar stabilization by Brd4 
has been reported for the E2 proteins from bovine papillomavirus [74], HPV 11 [68,75], and HPV 31 
[68]. Brd4 directly binds to transactivation domain (TAD) of E2 which suggests that Brd4 may be a 
universal regulator of E2 stability through competition with E3 ligase complexes that ubiquitinate the 
TAD domain [68]. Alternatively, a recent report suggests that E2 is primarily ubiquitinated in the 
cytoplasm and that Brd4 stabilizes E2 by sequestering it in the nucleus, where it is not accessible for 
degradation [76]. 
In addition to Brd4, several other proteins have been shown to increase E2 half-life by preventing 
proteosomal degradation, including two cellular proteins, Tax1BP1 [77] and NRIP [78], and two HPV 
proteins, E1 [79] and E1^E4 [80]. None of these proteins had any significant effect on E2 transcript 
levels, thus, they appear to be acting at the protein level. For the two viral proteins, E1 and E1^E4, no 
mechanism was explored. Tax1BP1 is a subunit of an ubiquitin-editing enzyme complex [81] and binds 
E2 through the TAD region, consistent with Tax1BP1 potentially acting to protect E2 by 
deubiquitinating this domain. However, no reduction of E2 poly-ubiquitination was observed in the 
presence of Tax1BP1, so the mechanism of E2 stabilization remains undefined. Like Tax1BP1 and Brd4, 
NRIP also interacts with E2 through the TAD domain [78]. Unlike Tax1BP1, NRIP was able to reduce 
ubiquitination of 16E2 and this was related to dephosphorylation of E2 mediated via recruitment of 
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calcineurin by NRIP. Exactly how phosphorylation promotes or contributes to ubiquitination remains 
unclear, especially as other reports suggest that phosphorylation may stabilize 16E2 [82] and 8E2 [83]. 
An intriguing suggestion is that phosphorylation may regulate chromatin association leading to bound 
E2 that is protected from degradation, possibly by sequestration from the ubiquitination machinery, and 
is consequently much more stable than unbound E2 [83]. In this model phosphorylation could be a 
determinant of either stability or degradation depending on how it affected chromatin binding by a 
particular E2 type and during a particular cell cycle stage. 
Lastly, there is evidence that E2 degradation is subject to crosstalk between the ubiquitin system and 
the sumoylation system [84]. BPV, HPV 11, HPV 16, and HPV 18E2 proteins have all been shown to 
bind Ubc9, the SUMO conjugating enzyme, and the 16 and 18E2 proteins could be sumoylated in vitro 
and in vivo [85]. Type 16E2 was tested for functional effects, and sumoylation was found to contribute 
to both transactivation and repressive activity. In addition to these functional effects, increasing overall 
intracellular sumoylation levels led to a dramatic stabilization of 16 and 18E2 proteins via prevention of 
proteosomal degradation [86]. Surprisingly, the stabilization mediated by increasing overall sumoylation 
did not occur through direct sumoylation of the E2 proteins themselves as sumoylation defective E2 
mutants were stabilized as effectively as the wild-type protein. This indirect effect on E2 degradation 
suggests that increasing sumoylation regulates some component of the ubiquitination/deubiquitination 
pathway to prevent proteosomal degradation. Biologically this may contribute to enhanced E2 
expression in suprabasal layers of the skin where sumoylation is increased [87]. In summary, the overall 
levels of E2 reflect a complex interplay between numerous factors that can interact with E2 to  
facilitate or inhibit degradation, and there appear to be type specific nuances that further confound our  
current understanding. 
3.3. The E4 Proteins 
The E4 ORF is located within the E2 gene and is expressed primarily as an E1^E4 product [16]. The 
E1^E4 protein is expressed at relatively high levels during productive viral replication and accumulates 
in the mid to upper epithelial layers, suggesting that it is a fairly stable protein [88,89]. While 
modification of E1^E4 by kinases [90–92] and proteases [93,94] is known, modification by the ubiquitin 
superfamily members has not been reported. 
3.4. The E5 Proteins 
The E5 protein is the major oncoprotein for BPV and a contributor to the oncogenic process in HPVs 
[14]. It is a very small (44 amino acids for BPV and approximately 80 amino acids for HPVs), 
hydrophobic, and membrane associated protein that is expressed at very low levels. Like E4 proteins, 
the turnover and degradative mechanisms have not been explored in any detail, thus, whether or not it is 
modified by ubiquitin for proteosomal targeting is unknown. 
3.5. The E6 Proteins 
E6 proteins from high-risk HPV types are moderately short-lived proteins [95,96] that are degraded 
via the proteasome [53,97]. The degradative mechanism for other E6 proteins is less certain as an initial 
study reported that two low-risk genital type E6 proteins (6a and 11) were not stabilized by a proteasome 
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inhibitor and two cutaneous HPV E6 types (5 and 8) showed only slight stabilization by the 
inhibitor [53]. However, a subsequent study found that type 11E6 was ubiquitinated and degraded via 
the proteasome, suggesting that all E6 types may share a common degradative pathway [97]. Differences 
in epitope tagging or cell type for the expression experiments may account for these conflicting results, 
and further studies are needed to clarify possible differences in degradative mechanisms between various 
E6 types. In contrast, both studies agreed that this degradative process does not require interaction with 
E6AP, a known ubiquitin E3 ligase that binds E6 proteins [98]. Interestingly, a latter study found that 
the presence E6AP actually stabilizes both HPV 16 and 18E6, though the E6AP enzymatic activity is 
unnecessary for this protective effect [99], and similar results were later found for cutaneous HPV E6 
proteins [100]. The combined results infer that E6AP is not the E3 ligase responsible for ubiquitinating 
E6 itself, that E6AP is acting through some other mechanism to affect E6 turnover, and that this 
mechanism may be common to all E6 types. The true E3 ligase(s) for E6 proteins remains undetermined, 
but other possible candidates have been identified through recent proteomic approaches. HERC2, a 
putative E3 ligase of the HECT-domain type, was associated with HPV 16E6 [101], a HECT-domain 
E3 ligase, called EDD, binds strongly to HPV 18E6 and weakly to type 16 and 11 E6 proteins [102], 
and some E6 proteins from genus beta interact with the Ccr4-Not complex which has known ubiquitin 
ligase activity [6]. However, none of these candidates has been functionally tested for ability to 
ubiquitinate E6, thus, all may simply be E3 ligases recruited to E6 to facilitate modification of other 
substrates rather than E6 itself. For example, EDD enhances ubiquitination of E6AP and reduces E6AP 
levels which indirectly reduces E6 levels, but does not appear to affect E6 directly [102]. Likewise, 
HERC2 is known to stimulate the ligase activity of E6AP [103], so could be acting to enhance the 
activity of the E6-E6AP complex rather than targeting E6 itself. No such HERC2 enhancing effect was 
observed for E6-mediated p53 degradation in HeLa cells [104], but this does not rule out a possible 
HERC2 effect on other E6 targeted substrates. 
Lastly, in addition to binding E3 ligases, HPV 16E6 binds a deubiquitinating enzyme, USP15, and 
both 16 and18E6 proteins are stabilized by catalytically active, but not an inactive, mutant of 
USP15 [101]. These results suggest that USP15 is protecting E6 proteins by removing ubiquitin chains 
and are consistent with a typical ubiquitin-proteasome pathway for degradation of at least the high-risk 
HPV E6 proteins. Somewhat surprisingly, HPV 16E6 is also stabilized by association with PDZ domain 
proteins [105]. As PDZ proteins are themselves targets for E6-E6AP mediated degradation [106,107], 
this observation suggests that the complex network of interactions between E6 and its associated proteins 
can influence E6 stability and proteolysis, similar to what has been observed for E2 proteins. 
3.6. The E7 Proteins 
Like its partner oncoprotein, E6, the HPV E7 proteins are also short-lived with HPV 18E7, initially 
shown to have a half-life of less than 15 minutes in HeLa cells [108]. Subsequent studies of HPV 16E7 
in Cos 7 cells [54] and CaSki cells [109] both showed that E7 was ubiquitinated and that its short half-life 
was due to proteosomal-dependent degradation. The 16E7 half-life in Cos7 cells was 30-40 minutes, 
consistent with the high-risk E7 proteins, generally being short-lived proteins. Interestingly, mutational 
interrogation revealed that E7 degradation required the N-terminal eleven amino acids of E7 which 
directed N-terminal poly-ubiquitination of E7; neither of the two internal lysines in E7 was involved 
[54]. Tandem mass spectrometry (MS/MS) analysis of ubiquitinated HPV58 E7 confirmed N-terminal 
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conjugation of the ubiquitin moiety suggesting that this may be a general mechanism for E7 
ubiquitination [110]. 
While ubiquitin-mediated, proteosomal degradation of E7 proteins is well established, less certain are 
the components of the ubiquitination machinery that are specifically involved in E7 modification as 
several candidates have been identified. The first potential candidate identified was SOCS1 which binds 
E7 in vitro, co-localizes with E7 in vivo, stimulates E7 ubiquitination, and promotes proteosomal 
degradation of E7 [111]. SOCS1 is a component of the VCB-type ubiquitin E3 ligase that appears to 
function as an adapter protein to target this ligase to substrates [112], implying that SOCS1 is part of an 
E3 ligase complex that controls E7 degradation. However, it was noted the E7 was still partially 
ubiquitinated in the presence of an inactive SOCS-box defective mutant of SOCS1, suggesting that 
additional E3 ligases could be involved [111]. Consistent with this observation, Oh et al. demonstrated 
that the Cull1-Skp2 E3 ligase could also bind E7, function to ubiquitinate E7, and mediate E7 
proteosomal degradation [113]. Like the SOCS1 study, E7 degradation was only partially blocked in the 
absence of Skp2, thus, at least two E3 ligase pathways for E7 proteolysis seem plausible. Additionally, 
Oh et al. identified UbcH7 as a functional E2 ligase for E7 while seven other E2 ligases (UbcH2, UbcH3, 
Ubc5A, Ubc5B, Ubc5C, UbcH6, and UbcH10) were ineffective. Unfortunately, later studies have not 
demonstrated an association of E7 with cullin 1 [5,114], thus, the authentic E3 ligase complexes that 
ubiquitinate E7 remains uncertain. 
In addition to the dual E3 ligases that have been reported to facilitate E7 degradation, there is one 
report of a deubiquitinating enzyme (DUB) specific for E7, USP11 [115]. Both in vitro and in vivo, 
USP11 binds E7 and reduces the extent of poly-ubiquitination. Over expression of USP11 increases the 
half-life of E7 while siRNA knockdown of USP11 enhanced E7 degradation with a concomitant loss of 
E7 transforming activity in CaSki cells. While these studies do not rule out the existence of other DUBs 
that could contribute to the overall balance of ubiquitinated versus unmodified E7, they do strongly 
implicate a role for USP11 in at least some cell types. 
3.7. L1 and L2 Proteins 
The L1 and L2 capsid proteins are relatively stable and there are no reports of ubiquitination for either 
protein [9,10]. However, HPV16 L2 can be sumoylated at lysine 35 with a strong preference for 
SUMO2/3 over SUMO1 [50,116], and HPV16 L1 can be modified with ISG15 [117]. ISG15 modified 
L1 was incorporated less effectively into pseudovirion particles and the resulting modified pseudovirions 
had significantly reduced infectively, demonstrating that this modification could be regulating virion 
production during an authentic infection. Similarly, sumoylation of L2 prevents binding to L1, thus, 
sumoylation may also contribute to regulation of capsid assembly [50]. Sumoylation of L2 did not 
prevent binding to E2, but the effects of this modification on other known interactions of L2 were not 
examined. Interestingly, a lysine 35 to arginine mutant L2 protein had reduced stability compared to the 
wild type protein. However, the study did not distinguish whether sumoylation at lysine 35 actually 
protects L2 from degradation or that the arginine at position 35 simply makes L2 intrinsically less stable. 
Additionally, neither sumoylation nor ISGylation has been examined in the context of normal 
keratinocytes, so the presence and potential function of these modifications during the normal viral life 
cycle has not been verified. 
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4. Modulation of the Host Environment Mediated Through HPV-Ubl Interactions  
In addition to utilizing the ubiquitin-proteasome system, along with other Ubls, to regulate turnover 
of HPV polypeptides themselves, several HPV proteins have targeted these systems to control the levels 
and activities of critical cellular proteins. The ubiquitin superfamily, particularly ubiquitin and SUMO, 
modify hundreds to thousands of host proteins [118,119]. Redirecting these ubiquitous post-translational 
modifications systems provides the virus with enormous opportunities for reprogramming the cellular 
environment to favor viral persistence and reproduction. For HPVs, none of the viral proteins has 
intrinsic E3 ligase or deubiquitinating activity, so manipulation of these Ubl systems requires interaction 
between HPV proteins and cellular components of the ubiquitin or SUMO pathways. Retargeting host 
E3 ubiquitin ligases to new substrates to facilitate degradation of selected host proteins is an important 
mechanism for some HPV early proteins, particularly E6 and E7 [120]. Alternatively, some early 
proteins interfere with E3 ligases or recruit DUBs to prevent degradation of host proteins. Examples of 
how HPV proteins enhance, inhibit, and redirect the Ubl systems are presented below. 
4.1. The E1 Proteins 
While little is known about the specific enzymes involved in HPV E1 ubiquitination and proteasomal 
degradation, a recent association with a deubiquitinating complex has been described [121–123]. E1 
proteins from anogenital papilloma virus types, but not cutaneous types, interact with a host protein 
originally named p80 and, subsequently, called UAF1 [121]. UAF1 is a cytoplasmic protein that is 
recruited to the viral origin in an E1- and E2-dependent fashion and is necessary for wild-type levels of 
viral DNA replication [122]. However, UAF1 is not required for assembly of the E1-E2-ori complex so 
must be acting at a downstream point in the replication process. In addition to binding viral E1, UAF1 
interacts with three deubiquitinating enzymes, USP1, USP12, and USP46, leading to formation of a 
ternary complex on the viral origin, consisting of E1, UAF1, and any one of the three DUBs [123]. The 
presence of a DUB in the complex is as critical for replication activity as is UAF1 itself, suggesting that 
the primary role of UAF1 is to recruit a DUB to the replication initiation complex. What is missing at 
this point is the mechanism by which a DUB facilitates replication and the relevant target(s) for the 
DUB. Removal of ubiquitin from E1 to increase E1 levels is one possible mechanism to enhance 
replication, but the UAF1-USP complex is known to target other substrates involved in DNA replication 
and chromatin structure [124–126], thus, experimental determination of the functional targets will be 
needed to fully resolve how E1 utilizes host DUBs to promote viral genome replication. If the target(s) 
is not E1 itself, this would be a new example of how certain HPVs have usurped the ubiquitin system to 
target host proteins in ways that facilitate the viral life cycle. 
4.2. The E2 Proteins 
E2 is the major transcriptional regulatory protein for papillomaviruses, and it can exert either positive 
and negative effects on viral promoters depending on the context of E2 binding sites [12]. Over 80 host 
cell proteins have been identified as partners of various E2 types, many of them involved in 
transcriptional regulation and chromatin modification/remodeling as expected for a viral transcriptional 
regulatory protein. Among this group of known E2 partners is the E3 ligase, Mdm2 [70]. Mdm2 binds 
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to C-terminal DNA binding domain of E2, can complex with E2 on E2 binding sites, and activates 
E2-dependent transcription of the HPV 16 promoter. While transcriptional activation requires the E3 
ligase activity of Mdm2, E2 protein levels are unaffected by Mdm2 suggesting that E2 is not a direct 
substrate for Mdm2. Thus the transcriptional effects appears to be mediated via another mechanism 
involving ubiquitination, though the specific target for the E2-Mdm2 complex is still unknown. Potentially 
Mdm2 could be targeting other proteins associated with the HPV 16 promoter for proteolysis or affecting 
protein-protein interactions at the promoter, as is well established for other transcriptional units [127]. 
Perhaps because of a focus on E2’s transcriptional function, there has been very limited investigation 
of E2 interactions with the ubiquitin-proteasome system outside the context of transcriptional control. 
As mentioned in Section 3.2., high-risk E2 proteins type 16 and 18, but not low-risk E2s, associate with 
Cdc20 and Cdh1 (also known as FZR1) which are activators of the Anaphase Promoting Complex 
(APC), an important E3 ligase regulating cell cycle [71]. E2 appears to sequester Cdh1 into insoluble 
cytoplasmic structures, thus preventing APC activation and allowing APC substrates, such as cyclin B, 
to escape degradation. This dysregulation of APC ultimately leads to genomic instability which may 
contribute to the oncogenic potential of high-risk HPVs. 
The two above example confirm that E2 proteins can in some instances function as modulators of the 
ubiquitin-proteasome system, but until recently this mechanism seemed to be relatively limited for E2 
proteins. However, more global and unbiased evaluations of large-scale protein-protein interaction 
networks for multiple E2 protein types have revealed a more widespread connection between E2 and the 
ubiquitin-proteasome system [128,129]. A yeast two-hybrid screen of 12 different E2 types from three 
clades against a human keratinocyte (HaCaT) cDNA library revealed that proteins in the ubiquitin 
functional family comprised a major target for E2 proteins with 26 partner proteins identified [129]. 
Among these partners were two members of the HECT domain family of E3 ligases (HUWE1, WWP2) 
and several adaptor proteins of cullin-based ubiquitin ligases (BTBD1, SPOP, CDC20, CDH1, 
FBX022). While some of these interactions may be involved in ubiquitination and turnover of E2 itself, 
it is likely that some reflect novel pathways, whereby E2 redirects the ligases to new targets or modulates 
the ligase activity on their normal targets. Additionally, the interactor list contained PIAS1 and PIAS4, 
E3 ligases in the sumoylation pathway [130]. As E2 is known to be sumoylated [85], these PIAS proteins 
could be acting as SUMO ligases for E2, or again E2 could be retargeting them to enhance sumoylation 
of E2 partners. Regardless of the outcome, these more global interaction studies suggest that the ability 
of E2 to manipulate members of the ubiquitin super family may be broader and more extensive than 
previously considered. 
4.3. The E4 Proteins 
E4 proteins are known to mediate keratin network disruption which is believed to comprise epithelial 
integrity and promote virion release [131]. There is one report that at least part of the mechanism for this 
E4-mediated disruption of the keratin network is through hyper-ubiquitination of keratin proteins that 
are associated with E1^E4 protein, which could lead to enhanced proteosomal degradation of the keratins 
[132]. This hyper-ubiquitination is likely to be an indirect effect triggered by E1^E4 induced 
phosphorylation of the keratins rather than direct recruitment of an ubiquitin E3 ligase by E1^E4. 
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4.4. The E5 Proteins 
The HPV E5 oncoproteins are membrane bound and mediate their biological effects through 
association with several host cell proteins, including EGFR [133]. E5 enhances EGFR activity through 
multiple mechanisms, at least one of which appears to be interference with ubiquitin-proteasome 
degradation [134]. In this mechanism, HPV16 E5 reduced association of an E3 ligase, c-Cbl, with EGFR 
leading to a reduction in EGFR ubiquitination. The 16E5 effect on EGFR levels was similar to that seen 
by proteosomal inhibition, suggesting that interfering with the EGFR/c-Cbl interaction was an important 
contributor to E5 activation of EGFR. Similarly, 16E5 is reported to block the ubiquitin degradative 
pathway for keratinocyte growth factor receptor (KGFR), also by affecting the c-Cbl E3 ligase [135]. In 
this case E5 impairs phosphorylation at tyrosine 196 of the FRS2α docking protein that is constitutively 
associated with KGFR. Phosphorylation of this tyrosine is necessary to recruit the Grb2-Cbl ligase 
complex, so reduction of modification at this residue by E5 likely leads to reduced ability of the ligase 
to ubiquitinate the KGFR-KFS2 complex. 
In contrast to the above studies showing an E5-mediated inhibition of proteosomal degradation for 
two growth factor receptors, there are now two reports that E5 proteins can also enhance degradation of 
certain host proteins. CD1d is an important major histocompatibility complex (MHC) type 1 
glycoprotein that is down regulated at the protein level in HPV 6 or 16 E5 expressing cells; down 
regulation is abrogated by a proteasome inhibitor indicating a likely ubiquitin-proteasome degradative 
process [136]. In this case, E5 interacts with calnexin, an ER chaperone for CD1d, which likely results 
in misfolding of CD1d leading to its degradation. Decreased CD1d mediated by E5 results in abrogation 
of IL-12, a major cytokine important in both innate and adaptive immunity to pathogens, which would 
like aid in HPV evasion of the host immune response. While not a direct interaction between E5 and 
components of the ubiquitin-proteasome system, this example illustrates more subtle mechanisms by 
which the HPV proteins can influence the ubiquitin-proteasome system to the virus’ advantage. Another 
example of E5-mediated degradation has been reported for the pro-apoptotic protein, Bax [137]. 
Expression of HPV16 E5 increased ubiquitination of Bax leading to a decreased half-like that was 
rescued by a proteosomal inhibitor. E5 appeared to be acting through a pathway involving XOX-2, 
prostaglandin E2, and PKA, thus, again this is likely due to an indirect mechanism rather than a direct 
E5 interaction with components of the ubiquitin-proteasome system. As there are additional reports in 
the literature that E5 proteins can decrease the levels and/or half-lives of other cellular proteins 
[138,139], direct or indirect utilization of the ubiquitin-proteasome system by E5 may be a general 
feature of this viral protein. 
4.5. The E6 Proteins 
Historically, high risk E6 proteins are the prototype for HPV modulation of the host cell through the 
ubiquitin-proteasome system. Via their ability to bind the host ubiquitin ligase, E6AP, high risk E6 
proteins retarget the ligase to modify E6 partners and promote the proteosomal degradation of these 
partners [11]. At least for the high risk E6 proteins, knocking down E6AP levels has nearly the same 
effect on global gene expression as knocking down E6 itself [140], indicating that a large portion of E6’s 
functional effects are mediated through E6AP, either utilizing its E3 ligase activity or a possible 
transcriptional activity [141]. Furthermore, E6AP is necessary for E6 to cause cervical cancer in a mouse 
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model which strongly confirms that the oncogenic activity of the high risk E6 proteins is mediated 
through E6AP targets [142]. The initially described target of the E6-E6AP complex was the p53 tumor 
suppressor protein [143,144], and the ability of the high risk E6 proteins to promote p53 degradation 
remains a key element in the transforming activity of these proteins [145]. In addition to targeting p53, 
the high risk E6 proteins have a carboxy-terminal motif that can interact with cellular PDZ proteins and 
target their proteosomal degradation via E6AP [106,107,146–148]. The E6-targeted PDZ proteins that 
have been identified to date are membrane associated proteins involved in cell-to-cell adhesion and 
communication [149], thus, their dysregulation by E6-E6AP is likely to have significant effects on the 
host cells and may contribute to the oncogenic potential of the high-risk HPVs. However, the true extent 
to which these PDZ proteins are degraded in vivo during a natural infection and the actual biological 
consequences of such degradation remain largely unknown. 
While most early studies on HPV E6 proteins focused on the high-risk types, due to their importance 
in human cancers, more recent studies have shown interesting similarities and differences among various 
E6 types. For example, interaction with E6AP has also been shown for low risk mucosal HPVs 
[7,150,151], and this conserved ability to interact with E6AP occurs through the LXXLL motif on E6AP 
as for high risk E6 proteins [152–154]. However, in contrast to high risk E6 proteins, the low risk 
mucosal types fail to interact with or significantly degrade p53 even though they can bind E6AP 
[144,151,155]. This observation at least partially explains their low oncogenic potential and suggests 
that there must be subtle differences in the resulting E6-E6AP complexes between low and high risk 
mucosal E6 proteins that can affect target discrimination. Similarly, the low risk E6 proteins lack the 
PDZ binding motif so these proteins are not degraded by low risk E6s. Nonetheless, since the E6-E6AP 
interaction is conserved between high and low risk E6 types, there are likely to be other E6-E6AP targets 
that are biologically important for all mucosal HPVs.  
In support of a broader role for the E6-E6AP complex in the normal life cycle of HPVs, many other 
E6 binding partners have been identified both through targeted studies of individual proteins and more 
recently through proteomics approaches [6,7,102,156,157], and many of these partners are 
proteasomally degraded in an E6AP-dependent fashion. Discussion of all the numerous identified 
E6-E6AP targets is beyond the scope of this review, but more comprehensive discussions of individual 
targets can be found in several recent reviews [11,158–161]. Furthermore, the general importance of this 
E6-E6AP interaction has been extended by the recent demonstration that E6 proteins from cutaneous 
HPVs of the beta genus associate with E6AP [162]. However, there is considerable variation between 
individual E6 types and the extent of association with E6AP [100] and at least one report that several 
beta type E6 proteins do not bind E6AP [6], thus, the true generality of the E6-E6AP complex remains 
unresolved. Consistent with a possible general role for E6-E6AP, there is one common E6-E6AP targets for 
nearly all tested E6 proteins, Bak [163–165]. Bak is a pro-apoptotic protein [166], thus, down regulating 
its activity through degradation may be a critical requirement for all HPVs. In contrast, the more 
type-specific targets for E6-E6AP may reflect unique requirements for viral persistence and/or 
reproduction in different types of epithelium.  
The well-established and widespread ability of E6 proteins to interact with and utilize E6AP as an E3 
ligase to ubiquitinate host proteins for targeted degradation does not exclude interactions between E6 
and other components of the ubiquitin-proteasome system. As described in Section 3.5., proteomics 
approaches have demonstrated associations of various E6 proteins with other E3 ligases, including 
Viruses 2014, 6 3597 
 
HERC2 [101], EDD [102], and the Ccr4-Not complex [6]. What role these ligases play with E6 in the 
HPV life cycle, and what their potential targets might be, remain undefined. Additionally, there is 
accumulating evidence that E6 proteins can interact directly with proteosomal components. Two recent 
proteomics studies detected association of E6 proteins with multiple proteosomal subunits [6,7], and 
direct binding to multiple subunit proteins, including S2, S4, S6a and b, S7, S8, and S10 was 
demonstrated in vitro for 16E6, 11E6, and 18E6 [167]. E6 was also able to increase the ubiquitination 
of the S5a subunit through E6AP which increased S5a degradation [167]. How these proteosomal 
interactions may affect overall proteosomal function and/or degradation of E6 targets has not been 
examined, but does suggest that the utilization of the ubiquitin-proteasome system by E6 proteins is 
multi-faceted and complex. 
One other intriguing aspect of post-translational regulation by E6 is cross-talk between the ubiquitin 
and SUMO systems. The initial observation was that 16E6 binds PIASy, a SUMO E3 ligase, and inhibits 
its activity [168]. This reduction of PIASy activity results in decreased sumoylation of specific PIASy 
substrates, including p53 and pRb. PIASy normally activates p53 and represses pRb, thus, the E6 
mediated inhibition of PIASy would contribute to the reduced p53 activity and increased pRb activity in 
high risk HPV infected cells. Subsequently, a more global effect of E6 on the sumoylation system 
was demonstrated with the finding that the SUMO conjugating enzyme, Ubc9, is a substrate for 
E6AP-dependent degradation by high risk E6 proteins, leading to numerous changes in the cellular 
sumoylation profile [169]. Sumoylation is important in normal keratinocyte differentiation [87,170], 
thus, the ability of E6 to disrupt the sumoylation program broadly may contribute to the aberrant 
differentiation phenotype of high risk HPVs. Other more substrate specific possibilities exist, such as 
described in a recent study on hADA3, a transcriptional coactivator [171]. In the absence of E6, hADA3 
is a normal substrate for E6AP, and the ubiquitination and subsequent degradation of hADA3 is 
enhanced by its increased sumoylation. Expression of high risk E6 further enhances sumoylation of 
hADA3 thus leading to its decreased stability. While enhanced sumoylation of hADA3 might seem to 
conflict with generally reduced sumoylation caused by E6 targeting of Ubc9, on an individual substrate 
basis there may be no conflict. For example, recruitment of E6 to the E6AP-hADA3 complex could 
retarget E6AP to cause degradation of an associated SUMO protease resulting in a net increase in 
hADA3 sumoylation. While speculative, such models illustrate the additional levels of complexity that 
arise through cross-talk between the Ubl systems. Significant further studies will be needed to untangle 
and understand the biological consequences of these processes.  
4.6. The E7 Proteins 
Like E6, the characterization of E7 proteins has focused heavily on the major oncogenic types, 16, 
18, and 31, with many fewer studies on the low risk alpha types or the beta types [15]. The primary 
target for the high risk E7 proteins that is associated with their oncogenic potential is the host pRb protein 
which is degraded through the ubiquitin-proteasome pathway in an E7-dependent fashion [172–175]. 
MDM2, the natural E3 ligase for pRB is not involved in the E7-mediated degradation of pRB [176]. 
Instead, for HPV16 E7, a cullin 2 ubiquitin ligase associates with the E6-pRb complex, leading to pRB 
ubiquitination and degradation [114]. 16E6 preferentially associates with the activated NEDD8 modified 
form of cullin 2, and may induce neddylation and/or stabilize the neddylated form of cullin 2 [114]. 
However, 16E6 does not appear to bind directly to cullin 2, and association with cullin 2 requires the 
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substrate specificity factor, ZER1 [5]. Intriguingly, ZER1 interacts only with 16E7 and not 18E7, and 
18E7 does not directly bind to cullin 2 [114], thus, apparently, 18E7 utilizes a different E3 ligase to 
target pRb for degradation. Consistent with a requirement for another E7-associated E3 ligase, 
proteomics studies identify several other E3 ligase components, including KCMF1, UBR4, and cullin 3, 
that associate more generally with E7 proteins from alpha and beta HPV types [5]. What role these other 
potential E3 ligase complexes play in E7 modulation of the host environment is currently unknown, but 
the conservation of these interactions suggests that there are common functions across most, if not all, 
HPV E7 types that require the ubiquitin-proteasome system. One example of such a target is the pRB 
family member, p130, which is an important regulator of differentiation, cell growth, and senescence 
[177]. P130 is proteasomally degraded in an E7-dependent fashion by both high and low risk alpha HPVs 
[178–180]. While the specific E3 ligase components involved are undetermined, this critical regulatory 
protein could be a mandatory target for mucosal E7 proteins to facilitate a replicative environment in 
terminally differentiating keratinocytes; there is very little information about the role of p130 for the 
cutaneous types, though HPV1 has been reported to destabilize p130 in raft cultures [181]. 
In addition to the direct targeting of host proteins through complex formation between E7, E3 ligases, 
and the substrate, E7 also indirectly influences the ubiquitin-proteasome system to modulate levels of 
some host proteins. Spardy et al. demonstrated that 16E7 accelerates claspin degradation which helps 
abrogate DNA damage checkpoint responses and facilitates mitotic entry [182]. Claspin is normally 
targeted for proteosomal degradation through ubiquitination by the SCFβ-TrCP type E3 ligase, and 16E7 
up regulates several components of this complex presumably leading to increased ligase activity 
and enhanced modification/proteolysis of claspin. As the unregulated components all possess 
E2F-responsive promoter elements, it is likely that E2F activation resulting from E7-mediated 
degradation of pRb is the responsible for the increased expression of these components rather than a 
direct association of E7 with the SCF complex. A similar E2F-dependent mechanism appears to be 
involved in E7 regulation of the APC/C E3 ligase complex [183]. HPV16 E7 expression inhibits the 
degradation of APC/C substrates, such as cyclin A and cyclin B, during mitotic progression [184], and 
this inhibition is related to increased expression of EMI1, a negative regulator of APC/C [183]. At least 
part of the increased EMI1 levels results from increased transcription, again likely due to E2F activation 
following pRB degradation. Additionally though, EMI1 is also stabilized at the protein level by E7 
though the precise mechanism has not been determined. This combination of transcriptional and 
post-transcriptional effects raises EMI1 levels sufficiently to abrogate normal APC/C function. 
Decreased APC/C activity has been proposed to be a general requirement to create a nuclear environment 
permission for viral replication [185], thus, targeting APC/C via E7 is likely to be functionally significant 
for high-risk HPVs. Together, these two examples clearly illustrate the E7 proteins can also manipulate 
the ubiquitin-proteasome system via indirect pathways that do not require direct interaction of E7 with 
the ubiquitination machinery.  
Lastly, like E6, high risk 16E7 can associate with at least one proteosomal component, S4 [186]. This 
same subunit is also up regulated by E7 [187], though no information is available about mechanisms or 
the functional significance of E7-S4 interaction. Nonetheless, this ability to interact with a proteosomal 
component suggests additional complexity in the relationship between E7 and the ubiquitin-proteasome 
system that needs further exploration.  
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4.7. L1 and L2 Proteins 
Modulation of the ubiquitin superfamily by L1 and L2 has not been reported, but two recent 
publications have identified intriguing interactions of L2 with the sumoylation system. Marušič et al. 
found the HPV16 L2 expression in U2OS cells caused an increase in nuclear SUMO2/3 accumulation 
that did not require sumoylation of L2 itself [50]. While the functional significance of this L2-mediated 
up regulation is unknown, sumoylation has been shown to increase and be necessary during normal 
keratinocyte differentiation [87] and to be decreased by high risk E6 proteins [169], so perhaps L2 is 
acting to modulate the E6 effect in the higher layers of the epithelium. In addition to modulating host 
sumoylation, HPV16 L2 has been shown to have a functional SUMO interaction motif (SIM) that 
directly binds SUMO2 more strongly than SUMO1 [116]. The functional SIM was localized to amino 
acids 284-289, and this sequence is highly conserved among the high-risk L2 proteins. Mutation of this 
SIM motif had no effect on capsid assembly, binding to host cells, or intracellular trafficking, but 
abrogated the normal association of the L2-DNA complex with PML bodies and greatly reduced infectivity 
of HPV 16 pseudoviruses. These results strongly suggest that the L2 protein has evolved a SIM motif to 
facilitate localization of the viral genome to PML bodies during in the initial infection process. 
5. Conclusions 
Human papillomaviruses have evolved an incredibly varied and complex set of interactions with the 
host cell ubiquitin-proteasome system and some of the related Ubl modifier systems. Since the discovery 
of the E6-E6AP complex and its role in p53 ubiquitination and degradation 20 years ago, there is now 
evidence that most of, if not all, the viral proteins are either modified by one or more of the Ubl systems 
or exert an effect on how these systems modify and regulate host proteins. While many details remain 
to be determined, it is clear that these protein modifier based post-translational systems are of central 
importance for HPVs to effectively co-opt the host cells for viral reproduction. Initial studies with high 
risk mucosal HPVs confirmed that targeted degradation of critical host cell growth regulatory proteins, 
such as p53 and pRB, was essential for the transformation process. Subsequent examinations of low risk 
mucosal types and cutaneous types have confirmed that utilization of the ubiquitin-proteasome system 
is a more general feature of HPVs to regulate levels of their viral proteins and to impact the host cell 
environment. Burgeoning studies on other Ubl systems, primarily the SUMO system, have revealed 
examples where HPVs modulate or utilize sumoylation to regulate viral activities. Additionally, there 
are novel examples of HPV proteins exhibiting cross-talk between the ubiquitin and sumoylation 
systems, which adds another level of complexity to the ability of HPVs to modulate the host cell growth 
and differentiation processes. Hopefully, the next 20 years will be as productive as the previous 20 years 
in fully unraveling the mechanisms by which HPVs utilize the ubiquitin family of modifiers to reprogram 
host cells. 
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